Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 26/04/2016 Photo showing a bottle with medicine that is dropped onto a spoon.

    Methadone for cancer treatment? Clinical trials are needed to prove the effectiveness of this opioid

    Claudia Friesen, an oncologist at Ulm University Hospital, has achieved what many scientists dream of: she has made a discovery that has increased existing knowledge, and can be used to help people. People with cancers that are resistant to all conventional therapies who have been given methadone for pain relief in combination with conventional chemo- or radiation therapy, have reported that tumours have shrunk or disappeared completely. Clinical…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/methadone-for-cancer-treatment-clinical-trials-are-needed-to-prove-the-effectiveness-of-this-opioid
  • Article - 11/04/2016 Schematic representation of a big, blue, spherical virus.

    Glycovirology: carbohydrate molecules against infections

    Many viruses enter cells by way of carbohydrate molecules known as glycans to which they bind during the initial steps of infection. However, it is still largely unknown how glycan-mediated infection proceeds. This is about to change with a working group that has been set up by the DFG at the University of Tübingen and five other universities. The group will focus on glycovirology, a new scientific area that aims to understand the…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/glycovirology-carbohydrate-molecules-against-infections
  • Article - 13/01/2016 Drawing from the book "Max and Moritz" showing teacher Lämpel about to go to bed. A prohibition sign is    drawn across the bed.

    New approach for treating depression

    Depression is the most common mental health condition; it must be taken seriously and requires treatment. Exactly how and where therapies work is still unclear. Prof. Dr. Dietrich van Calker and Prof. Dr. Knut Biber from Freiburg University Medical Center have been looking into mechanisms of action and have discovered a molecule that appears to be implicated in numerous neuropsychiatric disorders and the effect of various anti-depression…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-approach-for-treating-depression
  • Article - 07/01/2016 Schematic showing a B-cell receptor in the plasma membrane and the protein Kidins220.

    New protein helps B cells generate an effective immune response

    The human immune system plays a key role for human health. Dr. Gina Fiala, a scientist in Prof. Dr. Wolfgang Schamel’s team in the Department of Immunology at Freiburg University, has discovered Kidins220/ARMS in B cells. Kidins220/ARMS is part of the adaptive immune system where it plays a key role in the maturation of B cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/kidins220-hilft-b-zellen-bei-der-immunabwehr
  • Article - 03/09/2015 Coloured photo of Patrick Müller touching a shelf with a fish tank with zebrafish.

    Pattern formation: How undifferentiated cell clusters develop orderly structures

    Dr. Patrick Müller explores cellular signalling pathways that turn undifferentiated cell clusters into orderly structures as embryos develop. Supported by an ERC grant, the Max Planck researcher from Tübingen uses a broad range of methods from the fields of genetics, biophysics, mathematics and the computer sciences for his investigations. Regenerative medicine is one field that particularly stands to benefit from Müller’s findings.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/pattern-formation-how-undifferentiated-cell-clusters-develop-orderly-structures
  • Press release - 26/08/2015 Immatics Logo

    Immatics Biotechnologies GmbH - new alliances and launch of Immatics US, Inc.

    MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology. Furthermore Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-biotechnologies-gmbh-new-alliances-and-launch-of-immatics-us-inc
  • Article - 26/05/2015 The photo shows two scientists looking into the camera.

    Novel effect of B-Raf inhibitors against bowel cancer discovered

    Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
  • Article - 27/04/2015 23122_de.jpg

    Newly discovered gene mutation favour obesity

    Professor Martin Wabitsch from Ulm University Hospital has been studying the genetic causes of obesity for quite some time. The discovery of another cause of this complex condition that has key clinical consequences was recently published in the renowned New England Journal of Medicine. Despite the internationally acknowledged success of this research and in contrast to the view of the World Health Organisation and scientific organisations, the…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-gene-mutation-favour-obesity
  • Article - 16/03/2015 Microscopic image of liver tissue. The area in the centre of the image has an intense yellow-red colour.<br />

    The critical balance between liver fibrosis and liver regeneration

    When the liver has been damaged, a receptor protein of the hepatic stellate cells called endosialin controls the balance between liver repair and scar formation. A team of researchers from Heidelberg and Mannheim has shown that endosialin is a positive regulator of fibrogenesis and a negative regulator of hepatocyte proliferation. Endosialin therefore seems to be a promising therapeutic drug target in non-neoplastic settings.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-critical-balance-between-liver-fibrosis-and-liver-regeneration
  • Dossier - 09/03/2015 22868_de.jpg

    Advances in the study and treatment of liver diseases

    Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively. Fewer advances…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases
  • Press release - 09/03/2015 Phenex Logo

    Gilead Sciences aquires FXR-program of Phenex Pharmaceuticals AG

    Gilead Sciences, Inc. (Foster City, CA, U.S.A.) and Phenex Pharmaceuticals AG (Ludwigshafen/Heidelberg, Germany), a privately-held biotechnology company, announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH).

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/gilead-sciences-aquires-fxr-program-of-phenex-pharmaceuticals-ag
  • Article - 22/12/2014 Schematic showing T-cell activation without and without CTLA4.

    The immune system – both weak and overreactive in the absence of CTLA4

    The ability to recognise a pathogen and combat it effectively is certainly one of the most complex and sophisticated processes the human body has evolved. People with an immunodeficiency or autoimmune disease may have a genetic defect in one of the genes involved in the immune response. Working with immunologists from London scientists Desire Schubert and Prof. Dr. Bodo Grimbacher from the Centre for Chronic Immunodeficiency CCI at the Freiburg…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-immune-system-both-weak-and-overreactive-in-the-absence-of-ctla4
  • Article - 28/11/2014 18963_de.jpg

    Martin Plenio - turning Ulm’s quantum biology into a technology forge

    Quantum biology has the potential to become the next big research coup. Professor Martin Plenio, 46, director of the Institute of Theoretical Physics at Ulm University and one of the world’s leading quantum technologists, is right at the forefront. He has been Alexander von Humboldt Professor since 2009, and holds a part-time professorship at Imperial College London, where he was formerly chair of quantum physics.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/martin-plenio-turning-ulm-s-quantum-biology-into-a-technology-forge
  • Article - 24/11/2014 Three-dimensional microscopic representation of a synthetic vesicle that is invaded by bacteria.

    Lipid zipper triggers bacterial invasion

    Millions of people die each year from infections both in developing and industrial countries. There is still no effective treatment for a large number of diseases caused by pathogens. In order to treat infectious diseases effectively, we need to understand the mechanisms that bacteria use to infect human cells. The cytoskeleton of the host cell usually plays a key role in this process. Researchers at the University of Freiburg have discovered a…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/lipid-zipper-triggers-bacterial-invasion
  • Article - 17/11/2014 Microscope image of two nerve cells that are connected with each other.<br />

    About synapses and learning

    You can’t teach an old dog new tricks – the old proverb is not totally true. It is now known that the modulation of synaptic functions, including the formation of new neurons, still takes place in old age, although to a lesser extent than in childhood. The human brain stores memories in the form of neural activity patterns. Structural plasticity appears to be the basis for all learning processes. Physician Thomas Hainmüller and Prof. Dr. Marlene…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/about-synapses-and-learning
  • Article - 10/11/2014 22262_de.jpg

    Alzheimer: amyloid-beta triggers mitochondrial dysfunction

    Neurons are very sensitive to disturbances and many different functions are no longer able to work efficiently when the power supply is impaired. Prof. Dr. Chris Meisinger and his team at the Institute of Biochemistry and Molecular Biology at the University of Freiburg have found that amyloid-beta peptides block important enzymes in the mitochondria resulting in mitochondrial dysfunction.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/alzheimer-amyloid-beta-triggers-mitochondrial-dysfunction
  • Article - 13/10/2014 The photo shows a lit cigarette lying on an ashtray.

    Concepts for breaking the smoking habit

    Giving up smoking would mean an estimated 30 percent reduction in cardiovascular disease and a 90 percent reduction in cases of lung cancer, and that’s just in men. There are many arguments for giving up smoking. However, despite being highly motivated, many smokers fail to do so. Professional help is therefore available in the form of behavioural- and pharmacotherapy. The relevant guidelines in Germany have just been amended and now recommend a…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/concepts-for-breaking-the-smoking-habit
  • Article - 18/08/2014 The photo shows 7 staff members of VAXIMM GmbH.

    VAXIMM: Vaccines that impede cancer growth

    VAXIMM GmbH, a young biotechnology company from Mannheim, Germany, specialises in the development of vaccines for cancer treatment. The company’s first product candidate, VXM01, is a live oral vaccine that targets the VEGFR-2 receptor and hence the blood supply of tumours. VXM01 is currently undergoing clinical testing in pancreatic cancer patients.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/vaximm-vaccines-that-impede-cancer-growth
  • Press release - 15/07/2014 21805_de.jpg

    amcure Receives EUR 5 Million Funding for the Development of New Tumour Therapeutic Agents

    amcure GmbH, a spin-off from the Karlsruhe Institute of Technology (KIT), has closed a Series A financing deal amounting to a total of EUR 5 million. The funding comes from a consortium headed by LBBW Venture Capital, with participations from KfW, MBG Mittelständische Beteiligungsgesellschaft Baden-Wuerttemberg, S-Kap Beteiligungen Pforzheim, BioM AG as well as private investors. The company also receives subsidies from the German Ministry of…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-receives-eur-5-million-funding-for-the-development-of-new-tumour-therapeutic-agents
  • Article - 16/06/2014 Glioblastoma cells with a granular appearance that indicates that they have undergone apoptosis. Cell death can be induced by the addition of methadone.

    Methadone – the last step to becoming an anti-cancer drug

    It all began several years ago with a surprising discovery in the laboratory. Claudia Friesen, a chemist at Ulm University, discovered that leukaemia cells that were exposed to methadone died within a relatively short period of time. Seven years on and many papers later, what was once a rather exotic substance is now undergoing clinical testing in cancer patients.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/methadone-the-last-step-to-becoming-an-anti-cancer-drug
  • Article - 19/05/2014 21459_de.jpg

    Alcoholism: the molecular basis of addiction and deprivation

    Scientists at the Central Institute of Mental Health in Mannheim use rats and mice to study the genetic basis and neurobiological mechanisms of alcohol addiction, the changes that occur during alcohol deprivation and the factors that favour a relapse. In translational research, the results from animal experiments are reviewed using alcohol-dependent patients in order to turn them quickly into preventive strategies and therapies.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/alcoholism-the-molecular-basis-of-addiction-and-deprivation
  • Article - 14/04/2014 Microscope image of cancer cells that have been exposed to UV light.

    New insights into apoptotic signalling networks

    Apoptosis, i.e. programmed cell death, is a precisely regulated process that leads to the elimination of surplus or damaged cells. The proteins of the Bcl-2 family play a key role in apoptosis. However, their complex interactions are not yet known in detail. A group of researchers from Germany, Austria and Switzerland is now trying to get to the bottom of this issue. Coordinated by the University of Konstanz, the researchers are jointly…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-insights-into-apoptotic-signalling-networks
  • Article - 31/03/2014 Microscopic image in which the nuclei and cytoskeleton are strained.

    Lsd1 – a gatekeeper for differentiation onset of embryonic mouse stem cells

    Epigenetics is an emerging field of research that studies heritable changes in gene expression that are not caused by changes in the underlying DNA sequence. Prof. Dr. Roland Schüle, Director of Central Clinical Research at the Freiburg University Medical Centre, and his team are specifically focused on epigenetic modifiers that regulate the timely development of placental mouse tissue. Schüle and his team have discovered in mouse embryos that a…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/lsd1-a-gatekeeper-for-differentiation-onset-of-embryonic-mouse-stem-cells
  • Article - 31/03/2014 21168_de.jpg

    The growing significance of peptide therapeutics

    The therapeutic use of peptides lags behind that of proteins. And there are good reasons for this. However, it seems that this is beginning to change and that peptide therapeutics are growing in significance. As a matter of fact, peptides have become rather popular candidates for drugs.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-growing-significance-of-peptide-therapeutics
  • Article - 17/03/2014 Schematic shows how the bacterial toxin kills insects.

    Bacterial toxins manipulate proteins that serve as signalling switches in the host cell

    The enterobacterial species Photorhabdus asymbiotica und luminescens live in symbiosis with predatory nematodes that infest insect larvae and feed on their victims. The bacteria wait in the worms gut until their symbiotic partner has crept into the larvae then they are released and kill the insect with an ingenious toxin cocktail. Researchers in the team led by Professor Aktories and Dr. Thomas Jank recently discovered a mechanism of one of the…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/bacterial-toxins-manipulate-proteins-that-serve-as-signalling-switches-in-the-host-cell

Page 2 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search